MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1
Clinical Trials Related to Cyclophosphamide
Related studies linked through entity extraction aliases.
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE3
Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE2
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3
- Status
- TERMINATED
- Phase
- PHASE2
Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC
- Status
- TERMINATED
- Phase
- PHASE2
Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)
- Status
- COMPLETED
- Phase
- PHASE2
CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Nivolumab With Chemotherapy in Refractory MDS
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis
- Status
- UNKNOWN
- Phase
- PHASE2
Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Blood Stem Cell Transplant for Sickle Cell Disease
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer.
- Status
- COMPLETED
- Phase
- PHASE2
Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
- Status
- TERMINATED
- Phase
- PHASE2
Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1